On November 5, 2015 Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported that preclinical research on G100, Immune Design’s intratumoral TLR4 agonist-based product candidate, will be presented in an oral presentation at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting taking place December 5-8, 2015 in Orlando, Florida (Press release, Immune Design, NOV 5, 2015, View Source [SID:1234507982]). The abstract was posted today on the ASH (Free ASH Whitepaper) website at www.hematology.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal ResponsesFL
Abstract Number: 820
Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Immune Modulation and Microenvironment in Lymphoma
Date and Time: Monday, December 7, 2015 at 5:15 p.m. Eastern, during 4:30 – 6 p.m. session
Location: Orange County Convention Center, Hall E2
Presenter: Idit Sagiv-Barfi, Stanford University School of Medicine